These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37217910)

  • 1. Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha.
    Liu Y; Zheng Y; Lin X; Cao Z; Lu J; Ma L; Ren S; Zheng S; Hu Z; Xu B; Chen X
    BMC Endocr Disord; 2023 May; 23(1):115. PubMed ID: 37217910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
    Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
    Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can pegylated interferon α 2a cause development of thyroid disorders in patients with chronic hepatitis B?
    Kozielewicz D; Zaleśna A; Dybowska D
    Expert Opin Drug Saf; 2014 Aug; 13(8):1009-14. PubMed ID: 24930451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB; Golge N; Akin MS
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevalence and clinical characteristics of thyroid disease induced by chronic hepatitis B treated with polyethylene glycol (peg) interferon-alpha].
    Chen XF; Chen XP; Ma XJ; Chen WL; Huang J; Luo XD
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Apr; 26(2):117-9. PubMed ID: 23002550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X; Yu JX; Xie L; Ma WJ; Wang LH
    Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
    Chang YK; Tseng YT; Chen KH; Chen KT
    BMC Endocr Disord; 2019 Apr; 19(1):36. PubMed ID: 30953492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
    Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
    Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C.
    Pavan MH; Pavin EJ; Gonçales FL; Zantut-Wittmann DE; Wittmann DE
    Braz J Infect Dis; 2011; 15(5):449-56. PubMed ID: 22230851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
    Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
    World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.
    Li WC; Wang MR; Kong LB; Ren WG; Zhang YG; Nan YM
    BMC Infect Dis; 2011 Jun; 11():165. PubMed ID: 21651820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid dysfunction incidence and risk factors in Chinese chronic hepatitis B patients treated with pegylated interferon alpha: A long-term follow-up study.
    Ma Z; Qin Y; Jia Y; Xie Y; Qi X; Guo Y; He J; Zhang Y; Li F; Yu J; Zhu H; Yang F; Zhang Y; Mao R; Zhang J
    J Viral Hepat; 2022 Jun; 29(6):412-419. PubMed ID: 35293082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?
    Vezali E; Elefsiniotis I; Mihas C; Konstantinou E; Saroglou G
    J Gastroenterol Hepatol; 2009 Jun; 24(6):1024-9. PubMed ID: 19383078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
    Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review.
    Zhang Y; Chen B; Wang L; Chi J; Song S; Liu M; Zhao Z
    Rev Esp Enferm Dig; 2016 May; 108(5):263-70. PubMed ID: 27023755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interferon in hepatitis B].
    García Buey L; González Mateos F; Moreno Otero R
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():19-31. PubMed ID: 19100228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B.
    Fan H; Lin L; Jia S; Xie M; Luo C; Tan X; Ying R; Guan Y; Li F
    J Viral Hepat; 2019 Jul; 26 Suppl 1():77-84. PubMed ID: 31380586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010.
    Barut S; Gunal O; Erkorkmaz U; Yildiz F
    Braz J Infect Dis; 2012; 16(5):448-51. PubMed ID: 22964290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.